Form 8-K - Current report:
SEC Accession No. 0001104659-25-001109
Filing Date
2025-01-06
Accepted
2025-01-06 09:00:55
Documents
15
Period of Report
2025-01-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2432042d2_8k.htm   iXBRL 8-K 29182
2 EXHIBIT 99.1 tm2432042d2_ex99-1.htm EX-99.1 17686
6 GRAPHIC tm2432042d2_ex99-1img001.jpg GRAPHIC 2331
  Complete submission text file 0001104659-25-001109.txt   231400

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeon-20250106.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeon-20250106_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeon-20250106_pre.xml EX-101.PRE 22369
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2432042d2_8k_htm.xml XML 3807
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 25509187
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)